 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
With Primate Testing on Deck, nLife Aims at Partnerships for Neuron Delivery Technology
February 28, 2013
With Primate Testing on Deck, nLife Aims at Partnerships for Neuron Delivery Technology
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Former Traversa Exec Forms New Company to Develop Oligo-modification Tech
May 16, 2013 / Gene Silencing News - RNAi Drug Delivery Startup Solstice Closes $18M Series Financing Round
January 10, 2013 / Gene Silencing News - Alnylam Forms Alliance with Genzyme in ATTR, Adds Another Notch to Partnership Belt
October 25, 2012 / Gene Silencing News - UT Southwestern Team Publishes Details on Duplex RNA Inhibition of Huntington's Disease Gene
October 18, 2012 / Gene Silencing News - Isis Studies Suggest Therapeutic Potential of Single-Stranded RNAi Molecules
September 6, 2012 / Gene Silencing News